RNS Number : 7870E
Craven House Capital PLC
03 July 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018. 

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

The Board of Craven House notes the announcement released earlier today by Hemcheck Sweden AB ("Hemcheck").  Further to its investee company update released at 7:00AM on 8 February 2023, which outlined that its investee company Bio Vitos was being acquired in a share exchange transaction by Nasdaq listed Hemcheck, Craven House now announces that whilst the acquisition by Hemcheck has now been completed and approved by Hemcheck shareholders, the prior approval application submitted to Nasdaq Stockholm, by Hemcheck, has not been approved by Nasdaq. Hemcheck and Bio Vitos have therefore entered into a supplementary agreement that will enable current operations to remain in operation whilst an updated re-listing application is submitted by Hemcheck to Nasdaq.

Bio Vitos anticipates that it will receive its shares in Hemcheck before the end of July 2023 which will be passed directly onto the Bio Vitos shareholders, which include Craven House. Craven House's 24.5% holding in Bio Vitos, will remain unchanged. 

Further announcements will be made in due course as appropriate. 

 

For further information please contact:

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 0203 286 8130

 

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/James Keeshan

www.Sparkadvisorypartners.com

 

Tel: 0203 368 3550

 

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFFFDAIVIIV